These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 19232272

  • 1. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S.
    Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
    [Abstract] [Full Text] [Related]

  • 2. [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
    Villavicencio C, Ramírez-Sarmiento A, Gayete A, Grau S, Orozco-Levi M.
    Arch Bronconeumol; 2007 Sep; 43(9):519-22. PubMed ID: 17919420
    [Abstract] [Full Text] [Related]

  • 3. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 4. [Recurrent nerve paralysis and pleural effusion due to cabergoline].
    Muñoz-Morente A, Garcia-Trujillo L, Soto-Hurtado EJ, González-Benítez MA.
    Rev Neurol; 1992 Feb; 46(6):382-3. PubMed ID: 18368686
    [No Abstract] [Full Text] [Related]

  • 5. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
    Sato T, Kikuchi A, Onoue N, Hiramoto T, Oumi M, Onodera J.
    Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pleural fibrosis associated with dihydroergocryptine treatment.
    Oechsner M, Groenke L, Mueller D.
    Acta Neurol Scand; 2000 Apr; 101(4):283-5. PubMed ID: 10770528
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Levin J, Neudert J, Zwermann L, Näbauer M, Bötzel K.
    J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
    [No Abstract] [Full Text] [Related]

  • 10. [Pleural effusion and severe edema of the lower limbs induced by bromocriptine].
    Messiaen T, Lefebvre C, Weynand B, Pieters T.
    Rev Med Interne; 1996 Nov; 17(8):680-3. PubMed ID: 8881198
    [Abstract] [Full Text] [Related]

  • 11. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK.
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [Abstract] [Full Text] [Related]

  • 12. Cabergoline-related severe restrictive mitral regurgitation.
    Pinero A, Marcos-Alberca P, Fortes J.
    N Engl J Med; 2005 Nov 03; 353(18):1976-7. PubMed ID: 16267335
    [No Abstract] [Full Text] [Related]

  • 13. [Reversible cardiac valve abnormalities with pergolide treatment].
    Calomne V, Dupuis MJ, Muller T, Kempinere F.
    Rev Neurol (Paris); 2004 Jan 03; 160(1):81-2. PubMed ID: 14978397
    [Abstract] [Full Text] [Related]

  • 14. [Mitral valve replacement for cabergoline-related severe mitral regurgitation].
    Hanada T, Shimizu K, Murakami R, Ota T, Okada S, Inoue S, Hiroe K, Higaki Y, Oda T.
    Kyobu Geka; 2007 Oct 03; 60(11):1018-21. PubMed ID: 17926907
    [Abstract] [Full Text] [Related]

  • 15. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Oct 03; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 16. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
    Lökk J.
    Lakartidningen; 2008 Oct 03; 104(40):2892-4. PubMed ID: 17966806
    [No Abstract] [Full Text] [Related]

  • 17. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP, Perry CM.
    Drugs; 2004 Oct 03; 64(18):2125-41. PubMed ID: 15341508
    [Abstract] [Full Text] [Related]

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Oct 03; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 19. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG, Wilcox PG, Churg A, Fleetham JA.
    Arch Intern Med; 1988 Oct 03; 148(10):2231-6. PubMed ID: 3178380
    [Abstract] [Full Text] [Related]

  • 20. Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
    Fietzek UM, Riedl L, Ceballos-Baumann AO.
    Parkinsonism Relat Disord; 2012 Jun 03; 18(5):654-6. PubMed ID: 21908226
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.